Print

X001

A Phase 1 Open-Labelled Trial to Evaluate the Safety and Immunogenicity of CN54gp140 in HIV-Uninfected, Healthy Volunteers

Trial Details:

I Completed
Imperial College London, Wellcome Trust October 01, 2013
CN54gp140 Env C
CN54gp140 Protein
United Kingdom 12
NCT01966900
http://www.clinicaltrials.gov/ct2/show/NCT01966900?term=hiv+and+vaccine&lup_s=10%2F17%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14